Tests new drug candidates against placebo in adults with moderate to severe atopic dermatitis
Tests GHZ339 against placebo in adults with moderate to severe atopic dermatitis.
Plain-language title generated from the registry record
Registry title: Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Key facts
- Where
- Bardejov, Komarno, Košice, Kosice - Zapad, and Presov, SlovakiaSee the 5 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate to severe atopic dermatitis (eczema) to test investigational compounds against placebo.
- Age
- 18 to 100 years
- Sex
- All sexes can join.
- Disease stage
- Atopic dermatitis that is moderate to severe, with onset at least 1 year ago.
Main reasons for not taking part
- Clinically significant medical condition or infectious disease (specified in the sub-protocol)
- Clinically significant abnormal blood, chemistry, urine or ECG results
- Any other active inflammatory skin disease
- Chronic, uncontrolled medical condition, such as uncontrolled diabetes or high blood pressure
- Unstable disease that would likely need systemic corticosteroids, such as uncontrolled asthma
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06947993, who can take part
Where in Slovakia
- Maxderm s.r.o.Bardejov, SlovakiaTaking people
- Alergo H2b s.r.o.Komarno, SlovakiaTaking people
- Alersa s.r.o.Košice, SlovakiaTaking people
- Univerzitna nemocnica L. Pasteura KosiceKosice - Zapad, SlovakiaTaking people
- Medikard s.r.o.Presov, SlovakiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06947993EU 2024-519081-49-00
- Record updated
- 28 September 2026
- Original description
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).Read full original descriptionShow less
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Inclusion: Able and willing to sign the informed consent (IC); Patients with a diagnosis of AD and onset of disease for at least 1 year; Moderate to severe AD.
Exclusion: Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol); Participant with any other active inflammatory skin disease; Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension); Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma); Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements; Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG.